Pfizer awards more than $1 million in metastatic breast cancer research funding
- Details
- Category: Pfizer
Pfizer Inc. (NYSE:PFE) has awarded a total of more than $1 million in funding to five leading breast cancer advocacy organizations to support projects focused on metastatic breast cancer (MBC) scientific research and quality-of-life studies.
Selumetinib granted Orphan Drug Designation in the US for adjuvant treatment of differentiated thyroid cancer
- Details
- Category: AstraZeneca
AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation for the investigational MEK 1/2 inhibitor, selumetinib (AZD6244, ARRY-142886) for adjuvant treatment of patients with stage III or IV differentiated thyroid cancer (DTC).
Grants4Apps Accelerator 2016: You imagine, Bayer supports
- Details
- Category: Bayer
The Grants4Apps (G4A) Accelerator developed by Bayer invites health IT and technology startups to apply for the program's 2016 edition. This year, Bayer looks primarily into projects aimed at fostering patient-doctor feedback in the Women's Health field as well as those improving patient engagement in Cardiology, Oncology, Radiology and Ophthalmology, but Bayer is also interested in highly innovative software, hardware, technologies applied to digital health fields.
AstraZeneca completes acquisition of Takeda's respiratory business
- Details
- Category: AstraZeneca
AstraZeneca has completed the acquisition of the core respiratory business of Takeda Pharmaceutical Company Limited ("Takeda"). The agreement, announced in December 2015, includes the expansion of rights to roflumilast (marketed as Daliresp in the US and Daxas in other countries),
Ready. Raise. Rise. Campaign
- Details
- Category: Bristol-Myers Squibb
The Ready. Raise. Rise. campaign encourages everyone to raise and share a flag to salute those who have been touched by cancer, especially patients and caregivers, and learn more about a rapidly evolving area of research, Immuno-Oncology, which seeks to harness the body's own immune system to fight cancer.
Pfizer reports first-quarter 2016 results
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) reported financial results for first-quarter 2016 and updated certain components of its 2016 financial guidance. Reported revenues totaled $13.0 billion, an increase of $2.1 billion, or 20%, which reflects operational growth of $2.9 billion, or 26%, partially offset by the unfavorable impact of foreign exchange of $729 million, or 7%.
Bristol-Myers Squibb reports first quarter financial results
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the first quarter of 2016, which were highlighted by strong sales for Opdivo, Eliquis and our hepatitis C franchise along with significant regulatory milestones and key data in Immuno-Oncology.
More Pharma News ...
- One family's history of the rare condition Fabry disease through the generations
- What's the secret to living a full life? A new global survey reveals family comes first
- Bayer off to a successful start in 2016
- Merck brings international start-up-companies to Darmstadt and Nairobi
- 2016 Otto Bayer Award goes to Professor Dr. Dirk Trauner
- AstraZeneca launches integrated genomics approach to transform drug discovery and development
- Novartis delivered solid Q1 despite Gleevec loss of exclusivity